Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Single-Sequence Crossover Study in Healthy Subjects to Determine the Effect of an Inhibitor of Cytochrome P450 3A on Exposure to Relacorilant and Its Main Metabolites

Trial Profile

A Phase 1, Open-Label, Single-Sequence Crossover Study in Healthy Subjects to Determine the Effect of an Inhibitor of Cytochrome P450 3A on Exposure to Relacorilant and Its Main Metabolites

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2019

At a glance

  • Drugs Relacorilant (Primary) ; Itraconazole
  • Indications Cushing syndrome; Prostate cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Corcept Therapeutics
  • Most Recent Events

    • 09 Jan 2019 Planned End Date changed from 31 Dec 2018 to 31 Jul 2019.
    • 09 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 30 Jun 2019.
    • 03 May 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top